Sage Therapeutics Inc (SAGE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Barry E. Greene
Employees:
690
215 FIRST STREET, CAMBRIDGE, MA 02142
617-299-8380

Sage Therapeutics, Inc. develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor.

Data derived from most recent annual or quarterly report
Market Cap 1.144 Billion Shares Outstanding59.884 Million Avg 30-day Volume 945.777 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.37
Price to Revenue270.9834 Debt to Equity0.0 EBITDA-627.919 Million
Price to Book Value2.855 Operating Margin-5990.8398 Enterprise Value1.808 Billion
Current Ratio10.991 EPS Growth-0.163 Quick Ratio10.513
1 Yr BETA 0.7734 52-week High/Low 59.99 / 16.52 Profit Margin-5704.5801
Operating Cash Flow Growth-39.5282 Free Cash Flow to Firm (FCFF) TTM -418.285 Million Free Cash Flow to Equity (FCFE) TTM-435.9 Million
Altman Z-Score13.3885
Earnings Report2024-02-15
View SEC Filings from SAGE instead.

View recent insider trading info

Sage Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding SAGE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SAGE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-08-11 by BARRETT ELIZABETH
  • 4: filed on 2023-06-16 by FEDERER JESSICA
  • 4: filed on 2023-06-16 by BARRETT ELIZABETH
  • 4: filed on 2023-05-11 by BARRETT ELIZABETH
  • 3: filed on 2023-03-17 by FEDERER JESSICA
  • 4: filed on 2023-03-17 by FEDERER JESSICA
  • 4: filed on 2023-03-17 by IGUCHI KIMI
  • 4: filed on 2023-02-23 by IGUCHI KIMI
  • 4: filed on 2023-02-15 by GAULT LAURA
  • 4: filed on 2023-02-15 by COOK ANNE MARIE

    • Events (8k)

  • 8-K: filed on 2023-11-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-31:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 8.01: Other Events
  • 8-K: filed on 2023-08-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-02-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BARRETT ELIZABETH

    • Director
    		 3,000 2023-08-09 3

    GREENE BARRY E PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-08-04 2

    JONAS JEFFREY M

    • Director
    		 0 2023-06-15 4

    COLA MICHAEL F

    • Director
    		 0 2023-06-15 1

    STARR KEVIN P

    • Director
    		 0 2023-06-15 1

    FRATES JAMES M

    • Director
    		 0 2023-06-15 1

    PAUL STEVEN M

    • Director
    		 0 2023-06-15 2

    GERMANO GENO J

    • Director
    		 0 2023-06-15 1

    GOLUMBESKI GEORGE

    • Director
    		 0 2023-06-15 2

    FEDERER JESSICA

    • Director
    		 0 2023-06-15 3

    IGUCHI KIMI CFO & TREASURER

    • Officer
    		 65,560 2023-03-15 6

    COOK ANNE MARIE SVP, GC & SECRETARY

    • Officer
    		 0 2023-02-13 2

    ROBICHAUD ALBERT CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-02-13 2

    BENECCHI CHRISTOPHER CHIEF BUSINESS OFFICER

    • Officer
    		 0 2023-02-13 2

    GAULT LAURA CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-02-13 1

    KANES STEPHEN CHIEF MEDICAL OFFICER

    • Officer
    		 13,471 2021-10-19 0

    CLOONAN MICHAEL CHIEF BUSINESS OFFICER

    • Officer
    		 21,102 2021-02-10 0

    BIOGEN INC.

    BIOGEN MA INC.

    • 10% Owner
    		 6,241,473 2020-12-31 0

    NAYAK ASHA

    • Director
    		 10,000 2019-06-05 0

    ANDERSON THOMAS SEE REMARKS

    • Officer
    		 41,554 2017-02-06 0

    THIRD ROCK VENTURES II, L.P.

    THIRD ROCK VENTURES GP II, L.P.

    TRV GP II, LLC

    LEVIN MARK J

    TEPPER ROBERT I

    • 10% Owner
    		 3,170,750 2016-08-19 0

    PIEN HOWARD H

    • Director
    		 13,922 2016-06-22 0

    NELSEN ROBERT

    • Director
    		 1,232,649 2015-11-09 0

    ARCH VENTURE FUND VII LP

    ARCH VENTURE PARTNERS VII, L.P.

    ARCH VENTURE PARTNERS VII, LLC

    CRANDELL KEITH

    BYBEE CLINTON

    • 10% Owner
    		 No longer subject to file 2015-06-18 0

    STEBEN KENNETH E PRESIDENT

    • Officer
    • Director
    • 10% Owner
    		 0 2010-12-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SAGE THERAPEUTICS INC SAGE 2023-11-28 22:15:04 UTC 4.9119 0.4081 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 21:45:03 UTC 4.9119 0.4081 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 21:15:04 UTC 4.9119 0.4081 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 20:45:04 UTC 4.9119 0.4081 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 20:15:04 UTC 4.9119 0.4081 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 19:45:03 UTC 4.9119 0.4081 700000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 19:15:04 UTC 5.0235 0.2965 700000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 18:45:03 UTC 5.0235 0.2965 700000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 18:15:03 UTC 5.0235 0.2965 700000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 17:45:04 UTC 5.0235 0.2965 700000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 17:15:04 UTC 5.0235 0.2965 700000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 16:45:04 UTC 5.0235 0.2965 700000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 16:15:04 UTC 5.0235 0.2965 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 15:45:03 UTC 5.0516 0.2684 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 15:15:03 UTC 5.0516 0.2684 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 14:45:04 UTC 5.0515 0.2685 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 14:15:04 UTC 5.0515 0.2685 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 13:45:04 UTC 5.07 0.25 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 13:15:03 UTC 5.07 0.25 750000
    SAGE THERAPEUTICS INC SAGE 2023-11-28 12:45:04 UTC 5.07 0.25 750000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund SAGE -806.0 shares, $-58185.14 2019-12-31 N-PORT
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund SAGE -621.0 shares, $-44829.99 2019-12-31 N-PORT
    American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund SAGE -2065.0 shares, $-289698.85 2019-09-30 N-PORT
    American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund SAGE -6074.0 shares, $-852121.46 2019-09-30 N-PORT
    Trust for Professional Managers- Convergence Market Neutral Fund SAGE -1277.0 shares, $-66965.88 2020-08-31 N-PORT
    FundVantage Trust- Gotham Enhanced Index Plus Fund SAGE -135.0 shares, $-3877.2 2020-03-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund SAGE -118.0 shares, $-3388.96 2020-03-31 N-PORT
    AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund SAGE -695.0 shares, $-97501.55 2019-09-30 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund SAGE -184.0 shares, $-5284.48 2020-03-31 N-PORT
    JNL Series Trust- JNL/AQR Large Cap Relaxed Constraint Equity Fund SAGE -4859.0 shares, $-363696.15 2021-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund SAGE -100.0 shares, $-2058.0 2023-09-30 N-PORT
    AdvisorShares Trust- AdvisorShares Dorsey Wright Short ETF SAGE -14530.0 shares, $-299027.4 2023-09-29 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments